Patents by Inventor Huajing WANG

Huajing WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF
    Publication number: 20230080224
    Abstract: The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.
    Type: Application
    Filed: February 5, 2021
    Publication date: March 16, 2023
    Applicant: Agency for Science, Technology and Research
    Inventors: William SUN, Boon Ooi Patrick TAN, Huajing WANG, Thai Leong YAP, Shin Yee HONG, Cheng-I WANG, Ching-Wen HUANG, Shuet Theng LEE, Kah Fei WAN, Jian Duan Johnathan NG
  • ANTI-PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20210380698
    Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 9, 2021
    Applicant: ORIGINCELL THERAPEUTICS CO., LTD.
    Inventors: Bohua LI, Huajing WANG, Xiaowen HE
  • ANTI-PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20210261677
    Abstract: Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 26, 2021
    Applicant: ORIGINCELL THERAPEUTICS CO., LTD.
    Inventors: Bohua LI, Huajing WANG, Xiaowen HE
  • METHOD FOR PROMOTING IMMUNE CELL PROLIFERATION
    Publication number: 20210106620
    Abstract: Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 15, 2021
    Applicant: ORIGINCELL THERAPEUTICS CO., LTD.
    Inventors: Youguo LING, Hao GUO, Haili MA, Huijiao LI, Huajing WANG, Bi YING, Huanfeng YANG, Xiaowen HE